Today: 22 June 2026

Novo Nordisk Stock Gets Wegovy Pill Boost as Eli Lilly’s Foundayo Starts Slow

Novo Nordisk Stock Gets Wegovy Pill Boost as Eli Lilly’s Foundayo Starts Slow

Novo Nordisk’s Wegovy pill recorded 18,410 U.S. prescriptions in its second week, far outpacing Eli Lilly’s Foundayo at 3,707, according to IQVIA data cited by analysts. Novo’s shares rose $2.24 to $40.76, while Lilly’s fell $35.26 to $882.39. Novo said its oral semaglutide lowered HbA1c by 0.83 points more than placebo in a trial of adolescents with type 2 diabetes. The company plans to seek regulatory approval for pediatric use in 2026.
24 April 2026
··
Nvidia Stock Is Near a Record Again. The $300 Case Now Turns on Vera Rubin

Nvidia Stock Is Near a Record Again. The $300 Case Now Turns on Vera Rubin

Nvidia shares rose 4.7% to $209.07 Friday, nearing record highs ahead of its May 20 earnings report. Investors are focused on demand for Nvidia’s upcoming Vera Rubin AI platform and whether cloud customers will keep spending into 2027. The Philadelphia Semiconductor Index hit an all-time high as chip stocks rallied after Intel’s strong outlook. Nvidia reported $68.1 billion in fiscal Q4 revenue, up 73% from a year earlier.
24 April 2026
···
POET Stock Is Flying Again: The Marvell Link, AI Optics Buzz and Tax Fight Behind the Rally

POET Stock Is Flying Again: The Marvell Link, AI Optics Buzz and Tax Fight Behind the Rally

POET Technologies shares rose 27% to $14.93 in late-morning trading Friday after CFO Thomas Mika said the company received a purchase order linked to Marvell Technology. Marvell has not confirmed the order. POET reported $341,202 in Q4 revenue and a $42.7 million net loss, as it shifts from development to production. The rally follows news of Marvell’s acquisition of Celestial AI and reported Google talks.
24 April 2026
··
Scinai Stock Surges on $2.61 Million Private Placement as SCNI Bets on CDMO Expansion

Scinai Stock Surges on $2.61 Million Private Placement as SCNI Bets on CDMO Expansion

Scinai Immunotherapeutics shares soared 82% Friday after the company announced a $2.61 million private placement and warrant inducement to fund its contract drug-manufacturing and immunotherapy work. The financing includes the sale of 5.2 million ADSs at $0.48 each and new warrants, with closing expected around April 27. Scinai reported $1.6 million cash at year-end and a going-concern warning in its latest filing.
24 April 2026
·
Norfolk Southern Stock Slips as Fuel Shock Puts Its Profit Story to the Test

Norfolk Southern Stock Slips as Fuel Shock Puts Its Profit Story to the Test

Norfolk Southern reported first-quarter net income of $547 million, down from $750 million a year earlier, citing higher fuel costs and merger expenses. Revenue held steady at $3.0 billion, but operating income dropped to $877 million. Shares fell 0.5% as investors focused on fuel price pressures and weak freight volumes. Intermodal traffic slipped 4%, while coal tonnage rose 9% but brought in less revenue.
24 April 2026
···
Synopsys Stock Turns Back Toward AI Chip Race After New TSMC Design Push

Synopsys Stock Turns Back Toward AI Chip Race After New TSMC Design Push

Synopsys announced expanded collaboration with TSMC on advanced chipmaking and packaging for AI, unveiling new design and analysis tools for TSMC’s 3nm, 2nm, A16, and A14 nodes. Shares of Synopsys rose to $483.00 early Friday after an eight-day winning streak ended Thursday. Cadence and Siemens also updated TSMC-related design tools. The news coincided with TSMC’s North America Technology Symposium in Santa Clara.
24 April 2026
···
Joby Aviation’s LA Air Taxi Bet Gets a Rooftop Test as Investors Watch Certification

Joby Aviation’s LA Air Taxi Bet Gets a Rooftop Test as Investors Watch Certification

Reuben Brothers and Joby Aviation announced plans for an air-taxi vertiport at Park Elm Residences at Century Plaza in Los Angeles, using the South Tower’s helipad and adding charging and a passenger lounge. The project requires local, state, and federal approvals. Joby is still seeking commercial certification for its electric aircraft. Residents would be able to book flights within the Los Angeles area.
24 April 2026
··
Qualcomm Stock Jumps Before April 29 Earnings, But the AI Trade Has a Hard Test Ahead

Qualcomm Stock Jumps Before April 29 Earnings, But the AI Trade Has a Hard Test Ahead

Qualcomm shares surged 9.7% to $146.97 in early Friday trading ahead of its April 29 earnings report. The company forecasts fiscal Q2 revenue of $10.2–$11 billion and adjusted EPS of $2.45–$2.65, with handset chip sales near $6 billion. JPMorgan downgraded the stock, citing smartphone headwinds and data-center competition. Adobe traded nearly flat at $238.76 after a large buyback.
24 April 2026
··
American Express Stock Is Falling After a Q1 Earnings Beat. The Catch Is Travel.

American Express Stock Is Falling After a Q1 Earnings Beat. The Catch Is Travel.

American Express reported first-quarter earnings per share of $4.28, up 18%, and revenue of $18.9 billion, an 11% increase. Shares fell 4.3% premarket to $318.55 as investors focused on higher expenses and softer airline spending. Net income rose to $3.0 billion, while billed business climbed 9% to $428 billion. The company reaffirmed its 2026 outlook and plans increased marketing and technology spending.
24 April 2026
····
Regeneron Stock Is Back In Focus: Why Wall Street Sees More Upside After Trump Deal

Regeneron Stock Is Back In Focus: Why Wall Street Sees More Upside After Trump Deal

Regeneron shares rose 2.6% Thursday after the company announced a U.S. drug-pricing agreement and said it would offer its new Otarmeni gene therapy free in the U.S. The stock closed at $766.02, up for the week and month but down 1.3% year to date. Raymond James and Cantor Fitzgerald reiterated bullish ratings and high price targets ahead of first-quarter results due April 29.
24 April 2026
··
P&G Beats Wall Street, Then Warns of a $150 Million Cost Hit

P&G Beats Wall Street, Then Warns of a $150 Million Cost Hit

Procter & Gamble reported fiscal Q3 net sales of $21.2 billion, up 7%, and core earnings per share of $1.59, beating estimates. Organic sales rose 3%, the strongest in over a year, with beauty volumes up 5%. The company warned higher commodity and tariff costs tied to Middle East conflict will weigh on fiscal 2026 earnings, now expected at the low end of its range. P&G shares rose 2% in premarket trading.
24 April 2026
·
IREN Stock Faces May 7 Test as AI Data Center Pivot, Microsoft Deal and $6 Billion Share-Sale Risk Collide

IREN Stock Faces May 7 Test as AI Data Center Pivot, Microsoft Deal and $6 Billion Share-Sale Risk Collide

IREN Limited will report fiscal third-quarter results on May 7 after its shares rose 7.5% to $52.02, bucking a broader market decline. The company, once focused on bitcoin mining, now faces scrutiny over its AI data center expansion and large contracts, including a $9.7 billion deal with Microsoft. IREN’s AI Cloud Services revenue more than doubled last quarter but remains far below mining revenue.
24 April 2026
·····
Palantir’s $1.1 Billion Test: Swiss Bank Defends Stake as AI Contractor Wins New U.S. Work

Palantir’s $1.1 Billion Test: Swiss Bank Defends Stake as AI Contractor Wins New U.S. Work

Swiss National Bank Chairman Martin Schlegel defended the bank’s $1.1 billion stake in Palantir after Minneapolis activists urged a sale over the company’s work with U.S. immigration authorities. The SNB held 6.24 million Palantir shares at the end of 2025. Palantir shares fell 7.24% Thursday after a previous gain. Shareholders will vote June 3 on proposals for more human rights oversight.
24 April 2026
·
1 … 225 226 227 228 229 … 2,091

Stock Market Today

  • CSL's Trading Surge and Restructuring: Boosting Investor Confidence in Core Business
    June 21, 2026, 8:30 PM EDT. CSL Ltd (ASX:CSL) has seen renewed investor interest following a challenging period marked by earnings downgrades, operational setbacks in its plasma and vaccine divisions, and leadership changes. Heavy trading volumes and a defensive shift towards healthcare stocks coincide with anticipation for CSL's upcoming full-year results and dividend announcement. The company's FY2026 guidance indicates slightly lower revenue amid integration and plasma cost issues. While a key test of earnings stability approaches, investors remain cautious due to ongoing restructuring and cost pressures. Analysts' earnings forecasts vary, reflecting differing views on execution risks. CSL projects A$16.9 billion revenue and A$3.3 billion earnings by 2029, with a fair value estimate suggesting about 21% upside from current prices.

Latest articles

Cognizant (NASDAQ: CTSH) Slides 10% as Nasdaq-100 Exit Nears

Cognizant (NASDAQ: CTSH) Slides 10% as Nasdaq-100 Exit Nears

22 June 2026
Cognizant shares plunged 10.49% to $43.70, erasing $2.4 billion in equity value—more than its $2 billion 2026 buyback target—after Accenture’s narrowed growth outlook, a Berenberg downgrade, and looming Nasdaq-100 removal, even as S&P 500 and Nasdaq rallied; investors now eye Q2 guidance as the next key test.
Pentagon Could Outpace Tech Giants on Small Nuclear Projects

Pentagon Could Outpace Tech Giants on Small Nuclear Projects

22 June 2026
Valar Atomics’ Ward 250 became the first DOE-authorized advanced reactor built outside a national lab to achieve criticality, signaling a shift as U.S. defense demand accelerates small nuclear deployment, with the Army allocating over $2 billion for microreactors—moving the sector from policy to production and raising near-term demand expectations.
Go toTop